J Urol 2006, 176:500–504.PubMed 49. Meyskens FL Jr, McLaren CE, Pelot D,

Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al.: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008, 1:32–38. 50. Quemener V, Moulinoux JP, Havouis R, Seiler N: Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res 1992, 12:1447–1453.PubMed 51. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW: Levels of rectal mucosal Ipatasertib research buy polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 2010, 139:797–805. 805 e791PubMed 52. Levin VA, selleck chemicals Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al.: Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV

versus PCV for anaplastic gliomas. Clin Cancer Res 2003, 9:981–990.PubMed 53. Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 2008, 107:33–40.PubMed

54. Kubota S, Ohsawa N, Takaku F: Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo. Int J Cancer 1987, 39:244–247.PubMed 55. Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF: Effects of polyamine synthesis inhibitors on primary tumor features and metastatic RVX-208 capacity of human breast cancer cells. Clin Exp Metastasis 2005, 22:255–263.PubMed 56. MacDonald NJ, Steeg PS: Molecular basis of tumour metastasis. Cancer Surv 1993, 16:175–199.PubMed 57. Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 1983, 49:636–649.PubMed 58. Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol 2009, 174:1588–1593.PubMed 59. Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437–443.PubMed 60. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266–276.PubMed 61. Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38–47.PubMed 62. Beavon IR: SHP099 supplier Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol 1999, 52:179–188.PubMed 63.